IL246833B - New salts and their pharmaceutical preparations for the treatment of inflammatory disorders - Google Patents

New salts and their pharmaceutical preparations for the treatment of inflammatory disorders

Info

Publication number
IL246833B
IL246833B IL246833A IL24683316A IL246833B IL 246833 B IL246833 B IL 246833B IL 246833 A IL246833 A IL 246833A IL 24683316 A IL24683316 A IL 24683316A IL 246833 B IL246833 B IL 246833B
Authority
IL
Israel
Prior art keywords
salt
compound
disease
acid
cancer
Prior art date
Application number
IL246833A
Other languages
English (en)
Hebrew (he)
Other versions
IL246833A0 (en
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of IL246833A0 publication Critical patent/IL246833A0/en
Publication of IL246833B publication Critical patent/IL246833B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L63/00—Network architectures or network communication protocols for network security
    • H04L63/04—Network architectures or network communication protocols for network security for providing a confidential data exchange among entities communicating through data packet networks
    • H04L63/0428—Network architectures or network communication protocols for network security for providing a confidential data exchange among entities communicating through data packet networks wherein the data content is protected, e.g. by encrypting or encapsulating the payload
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L63/00—Network architectures or network communication protocols for network security
    • H04L63/06—Network architectures or network communication protocols for network security for supporting key management in a packet data network
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L63/00—Network architectures or network communication protocols for network security
    • H04L63/08—Network architectures or network communication protocols for network security for authentication of entities
    • H04L63/0861—Network architectures or network communication protocols for network security for authentication of entities using biometrical features, e.g. fingerprint, retina-scan
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L63/00—Network architectures or network communication protocols for network security
    • H04L63/20—Network architectures or network communication protocols for network security for managing network security; network security policies in general
    • H04L63/205—Network architectures or network communication protocols for network security for managing network security; network security policies in general involving negotiation or determination of the one or more network security mechanisms to be used, e.g. by negotiation between the client and the server or between peers or by selection according to the capabilities of the entities involved
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L67/00—Network arrangements or protocols for supporting network services or applications
    • H04L67/01—Protocols
    • H04L67/10—Protocols in which an application is distributed across nodes in the network
    • H04L67/104—Peer-to-peer [P2P] networks
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L67/00—Network arrangements or protocols for supporting network services or applications
    • H04L67/50—Network services
    • H04L67/51—Discovery or management thereof, e.g. service location protocol [SLP] or web services
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/80—Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/22—Processing or transfer of terminal data, e.g. status or physical capabilities
    • H04W8/24—Transfer of terminal data
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W92/00—Interfaces specially adapted for wireless communication networks
    • H04W92/16—Interfaces between hierarchically similar devices
    • H04W92/18—Interfaces between hierarchically similar devices between terminal devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Computer Security & Cryptography (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Computing Systems (AREA)
  • Computer Hardware Design (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Databases & Information Systems (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL246833A 2014-02-07 2015-02-04 New salts and their pharmaceutical preparations for the treatment of inflammatory disorders IL246833B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1402071.3A GB201402071D0 (en) 2014-02-07 2014-02-07 Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2015/052242 WO2015117981A1 (en) 2014-02-07 2015-02-04 Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
IL246833A0 IL246833A0 (en) 2016-08-31
IL246833B true IL246833B (en) 2022-07-01

Family

ID=50390572

Family Applications (1)

Application Number Title Priority Date Filing Date
IL246833A IL246833B (en) 2014-02-07 2015-02-04 New salts and their pharmaceutical preparations for the treatment of inflammatory disorders

Country Status (28)

Country Link
US (7) US9382247B2 (enExample)
EP (2) EP3842432A1 (enExample)
JP (2) JP2017505329A (enExample)
KR (1) KR102478614B1 (enExample)
CN (2) CN105960407A (enExample)
AR (1) AR099307A1 (enExample)
AU (4) AU2015215045B2 (enExample)
CA (1) CA2938219C (enExample)
CY (1) CY1124349T1 (enExample)
DK (1) DK3102575T3 (enExample)
EA (2) EA032596B1 (enExample)
ES (1) ES2853375T3 (enExample)
GB (1) GB201402071D0 (enExample)
HR (1) HRP20210194T1 (enExample)
HU (1) HUE053309T2 (enExample)
IL (1) IL246833B (enExample)
LT (1) LT3102575T (enExample)
MX (2) MX395415B (enExample)
NZ (1) NZ722603A (enExample)
PL (1) PL3102575T3 (enExample)
PT (1) PT3102575T (enExample)
RS (1) RS61450B1 (enExample)
SG (2) SG11201606433PA (enExample)
SI (1) SI3102575T1 (enExample)
SM (1) SMT202100060T1 (enExample)
TW (2) TWI792593B (enExample)
UY (1) UY35984A (enExample)
WO (1) WO2015117981A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2016248727B2 (en) * 2015-04-13 2021-04-01 Alfasigma S.P.A. Methods for the treatment of cardiovascular disorders
JP2018511620A (ja) * 2015-04-13 2018-04-26 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性障害の治療のための方法
WO2016205334A1 (en) 2015-06-16 2016-12-22 Vascular Strategies Llc Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
CN105198878B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105198880B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105198876B (zh) * 2015-09-18 2017-09-29 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物h晶型及其制备方法
CN105111206B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105198879B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105218539B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105111207B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN105198877B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物g晶型及其制备方法
WO2017106568A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
US20170173034A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
WO2017106566A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
CN105669669A (zh) * 2016-03-04 2016-06-15 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物的a晶型、b晶型、d晶型、g晶型和m晶型及其制备方法
US20190100519A1 (en) 2016-03-21 2019-04-04 Crystal Pharmatech Co., Ltd. Hydrochloride salt crystal of drug for treating or preventing jak-associated disease and preparation method thereof
CN109476662A (zh) * 2016-08-03 2019-03-15 苏州科睿思制药有限公司 一种jak1选择性抑制剂的新晶型及其制备方法和用途
CA3043396A1 (en) 2016-11-10 2018-05-17 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JOP20180018A1 (ar) * 2017-03-14 2019-01-30 Gilead Sciences Inc تركيبات صيدلية تتضمن مثبط jak
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
US10815227B2 (en) 2018-08-27 2020-10-27 Cadila Healthcare Limited Processes for the preparation of filgotinib
US11882438B2 (en) * 2018-10-29 2024-01-23 Zorday IP, LLC Network-enabled electronic cigarette
WO2020177705A1 (zh) * 2019-03-05 2020-09-10 苏州科睿思制药有限公司 Filgotinib的马来酸盐晶型CSI及其制备方法和用途
JP2022527512A (ja) * 2019-03-30 2022-06-02 ユニケム ラボラトリーズ リミテッド フィルゴチニブおよびその中間体の調製のための新規プロセス
WO2021044327A1 (en) * 2019-09-03 2021-03-11 Dr. Reddy's Laboratories Limited Solid forms of filgotinib maleate and processes thereof
CN114075188A (zh) * 2020-08-11 2022-02-22 南京柯菲平盛辉制药有限公司 芳香杂环酰胺类化合物及其制备方法和医药用途
AU2021397808A1 (en) * 2020-12-09 2023-07-06 Servatus Ltd Combination therapy for inflammatory disorders of the joints
CN113773322B (zh) * 2021-11-10 2022-02-11 奥锐特药业(天津)有限公司 一种Filgotinib的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149769A1 (en) * 2009-06-26 2010-12-29 Galapagos Nv 5-phenyl-[1,2,4 ]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2549632B2 (ja) * 1986-08-20 1996-10-30 三井石油化学工業株式会社 オレフインの重合方法
DE60016384T2 (de) 1999-01-29 2005-12-01 Chugai Seiyaku K.K. Chondrogonese promotoren und indolin-2-on derivate
EP1391211A1 (en) 2001-04-27 2004-02-25 Chugai Seiyaku Kabushiki Kaisha Chondrogenesis promoters
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
WO2004039816A1 (ja) * 2002-10-29 2004-05-13 Shionogi & Co., Ltd. セフェム化合物の無機酸塩の結晶
ES2264795T3 (es) 2003-02-14 2007-01-16 Pfizer Products Inc. Triazolo-piridinas como compuestos antiinflamatorios.
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
JP2008503712A (ja) 2004-06-21 2008-02-07 ガラパゴス・ナムローゼ・フェンノートシャップ 骨関節炎治療の方法及び手段
CA2577478A1 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds
US7524860B2 (en) 2004-10-07 2009-04-28 Pfizer Inc. Antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
CA2662074A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
AR066845A1 (es) 2007-06-05 2009-09-16 Takeda Pharmaceutical Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer
AR067562A1 (es) 2007-07-18 2009-10-14 Novartis Ag Compuestos heterociclicos inhibidores de kinasa
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
AU2008291075A1 (en) 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2296475A4 (en) 2008-06-20 2014-03-05 Genentech Inc TRIAZOLOPYRIDINE COMPOUNDS JAK KINASE INHIBITORS AND METHODS
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
EP2305673A4 (en) 2008-07-31 2011-11-02 Daiichi Sankyo Co Ltd CRYSTAL OF A THIAZOLIDINE CONNECTION AND METHOD FOR THE PRODUCTION THEREOF
CA2763900A1 (en) 2009-06-05 2010-12-09 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
EP2481738A1 (en) 2009-09-25 2012-08-01 Kyorin Pharmaceutical Co., Ltd. Maleic acid salt and crystal thereof
CN102146082A (zh) 2010-02-04 2011-08-10 江苏恒瑞医药股份有限公司 吡咯并n杂环类衍生物的可药用的盐、其制备方法及其在医药上的应用
JP2013049632A (ja) * 2011-08-30 2013-03-14 Kowa Co ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び／又は治療剤
SA112330992B1 (ar) 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP2863950B1 (en) 2012-06-22 2018-07-18 Galapagos NV Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
AU2016248727B2 (en) 2015-04-13 2021-04-01 Alfasigma S.P.A. Methods for the treatment of cardiovascular disorders
JP2018511620A (ja) 2015-04-13 2018-04-26 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性障害の治療のための方法
US20170173034A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
JOP20180018A1 (ar) 2017-03-14 2019-01-30 Gilead Sciences Inc تركيبات صيدلية تتضمن مثبط jak
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149769A1 (en) * 2009-06-26 2010-12-29 Galapagos Nv 5-phenyl-[1,2,4 ]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors

Also Published As

Publication number Publication date
NZ722603A (en) 2019-07-26
US10708263B2 (en) 2020-07-07
DK3102575T3 (da) 2021-02-08
US11667633B2 (en) 2023-06-06
JP2017505329A (ja) 2017-02-16
SMT202100060T1 (it) 2021-03-15
AR099307A1 (es) 2016-07-13
EP3102575B1 (en) 2021-01-13
AU2020260391A1 (en) 2020-11-19
SG11201606433PA (en) 2016-09-29
US20180007043A1 (en) 2018-01-04
AU2022235624A1 (en) 2022-10-20
TWI792593B (zh) 2023-02-11
AU2022235624B2 (en) 2023-11-23
PL3102575T3 (pl) 2021-07-26
US20250289816A1 (en) 2025-09-18
WO2015117981A1 (en) 2015-08-13
AU2019202441B2 (en) 2020-08-06
CN105960407A (zh) 2016-09-21
US20210269435A1 (en) 2021-09-02
EA032596B1 (ru) 2019-06-28
US12234235B2 (en) 2025-02-25
LT3102575T (lt) 2021-04-26
SG10202013187PA (en) 2021-02-25
MX2020003368A (es) 2020-07-29
HRP20210194T1 (hr) 2021-03-19
TWI767878B (zh) 2022-06-21
MX376000B (es) 2025-03-07
PT3102575T (pt) 2021-02-04
EA201990330A1 (ru) 2020-01-31
ES2853375T3 (es) 2021-09-15
AU2015215045B2 (en) 2019-01-24
HUE053309T2 (hu) 2021-06-28
KR20160110518A (ko) 2016-09-21
CA2938219C (en) 2023-01-24
CA2938219A1 (en) 2015-08-13
US10919890B2 (en) 2021-02-16
TW201613915A (en) 2016-04-16
AU2020260391B2 (en) 2022-07-28
IL246833A0 (en) 2016-08-31
KR102478614B1 (ko) 2022-12-16
UY35984A (es) 2015-09-30
JP2020097595A (ja) 2020-06-25
US20200244651A1 (en) 2020-07-30
US9382247B2 (en) 2016-07-05
MX395415B (es) 2025-03-19
EA201691584A1 (ru) 2017-01-30
GB201402071D0 (en) 2014-03-26
EP3102575A1 (en) 2016-12-14
EP3842432A1 (en) 2021-06-30
CN111499630A (zh) 2020-08-07
US20230406857A1 (en) 2023-12-21
MX2016010068A (es) 2016-11-15
AU2019202441A1 (en) 2019-05-02
AU2015215045A1 (en) 2016-08-11
RS61450B1 (sr) 2021-03-31
TW202229274A (zh) 2022-08-01
US20160376269A1 (en) 2016-12-29
CY1124349T1 (el) 2022-07-22
US20150225398A1 (en) 2015-08-13
SI3102575T1 (sl) 2021-04-30

Similar Documents

Publication Publication Date Title
US12234235B2 (en) Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2015215044B2 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
CN102482273A (zh) 作为jak抑制剂的5-苯基-[1,2,4]三唑并[1,5-a]吡啶-2-甲酰胺化合物
HK1231859A1 (en) Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HK1231859B (en) Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EA041895B1 (ru) Новые соли и их фармацевтические композиции для лечения воспалительных заболеваний